Abstract:Abstract Background/Aims JAK inhibitors (JAKi) were launched in the UK for rheumatoid arthritis in 2017. Licenced indications have subsequently expanded to include other inflammatory arthritides, inflammatory bowel disease, psoriasis and atopic dermatitis. Since then, there have been numerous safety warnings from regulatory bodies, with signals for cancer, venous thromboembolism and cardiovascular events. We set out to compare how these safety warnings have influenced prescribing behaviour for individual JAKi medications in England. Methods We analysed aggregate prescribing data from all NHS hospitals in England between January 2019 and July 2023. We compared monthly prescriptions issued for individual JAKi (tofacitinib, baricitinib, upadacitinib, filgotinib) across all licenced indications. Standardisation was performed using WHO Daily Defined Doses. We conducted interrupted time-series analyses to evaluate whether changes in prescribing behaviour occurred after: i) the initial press release for the ORAL Surveillance trial data (January 2021); and ii) the European Medicines Agency (EMA) safety committee warning for the JAKi class as a whole (October 2022). Results Overall, JAKi prescribing has increased year-on-year since 2019; however, striking differences exist for individual JAKi medications. Pre-2021, an estimated additional 93 patients per month were newly initiated on tofacitinib. After the ORAL Surveillance press release (January 2021), tofacitinib initiations decreased to 26 new patients/month (p < 0.001). Following the EMA safety warning (October 2022), tofacitinib prescribing fell sharply (71 fewer patients/month; p < 0.001). A similar pattern was observed for baricitinib - pre-2021: 145 new patients/month; post-Jan 2021: 15 new patients/month; post-Oct 2022: 60 fewer patients/month (all, p < 0.001). In contrast, prescriptions for the JAK1-selective inhibitors (upadacitinib and filgotinib) have increased markedly since 2021, with no apparent impact of the pan-JAKi safety warnings. In July 2023, baricitinib remained the most prescribed JAKi in England across all indications (175,245 defined daily doses [DDD]) followed by upadacitinib (154,510 DDD), tofacitinib (105,215 DDD), and filgotinib (72,445 DDD). Conclusion Prescribing of JAKi has changed markedly in association with emerging safety warnings, with significant reductions in prescriptions for tofacitinib and baricitinib. It is notable that warnings have emerged for the JAKi class as a whole, yet prescriptions for the JAK1-selective inhibitors, upadacitinib and filgotinib, have continued to increase. Explanations could include clinicians' interpretation of risk differences within the JAKi class, as well as external pressures such as price and licenced indications. Disclosure M.D. Russell: Honoraria; AbbVie, Biogen, Eli Lilly, Galapagos, Menarini. Grants/research support; Eli Lilly, Janssen, Pfizer, UCB. Z. Yang: None. B. Walter: None. E. Alveyn: None. K. Bechman: Grants/research support; Versus Arthritis/Pfizer. A. Miracle: None. D. Nagra: None. M.A. Adas: None. J.B. Galloway: Honoraria; Abbvie, Biovitrum, BMS, Celgene, Chugai, Gilead, Janssen, Lilly, Novartis, Pfizer, Roche, Sanofi, Sobi, UCB.

National and interprovincial prescribing patterns of JAK-inhibitors in Canada: a repeated cross-sectional analysis

OA39 The influence of safety warnings on the prescribing of JAK inhibitors in England: an interrupted time-series analysis

Analysis of publicly available adverse events reported for pediatric patients treated with Janus kinase inhibitors

P008 High response rate to Janus Kinase inhibitors after multiple biologic drug failures, across disease indications, in a District General Hospital: results from an audit of the prescribing, safety and efficacy of Janus Kinase inhibitor

A Review on the Safety of Using JAK Inhibitors in Dermatology: Clinical and Laboratory Monitoring

P629 JAK inhibitor safety in Inflammatory Bowel Disease: real-world data comparing the effect of JAK inhibitors on blood parameters and their clinical significance

P790 Assessment of steroid use in patients with active ulcerative colitis who initiated a new Janus kinase inhibitor or tumour necrosis factor inhibitor using data from a United States claims database

Evaluating the Usage of Janus Kinase Inhibitors in Rheumatology and Its Impact on Cardiovascular Risk

Analysis of the association between Janus kinase inhibitors and malignant skin tumors using the Food and Drug Administration Adverse Event Reporting System

Clinician and patient views on janus kinase inhibitors in the treatment of inflammatory arthritis: a mixed methods study

Real-World Experience With Janus Kinase Inhibitors in Immune-Mediated Diseases: Clinical Experience of a University Hospital

JAK Inhibitors in Rheumatoid Arthritis: An Evidence-Based Review on the Emerging Clinical Data

Therapeutic Maintenance of Janus Kinase Inhibitors in Real Life for Rheumatoid Arthritis: Retrospective Study

Managing Cardiovascular and Cancer Risk Associated with JAK Inhibitors

Janus Kinase and Tyrosine Kinase Inhibitors in Dermatology: A Review of Their Utilization, Safety Profile and Future Applications

JAK-inhibitors and risk on serious viral infection, venous thromboembolism and cardiac events in patients with rheumatoid arthritis: A protocol for a prevalent new-user cohort study using the Danish nationwide DANBIO register

Persistence of Janus-kinase (JAK) inhibitors in rheumatoid arthritis: Australia wide study

JAK Inhibitors: Prospects in Connective Tissue Diseases

The efficacy and safety of different Janus kinase inhibitors as monotherapy in rheumatoid arthritis: A Bayesian network meta-analysis

JAK inhibitors in refractory juvenile rheumatic diseases: Efficacy, tolerance and type-I interferon profiling, a single center retrospective study

A Comprehensive Overview of Globally Approved JAK Inhibitors